Boehringer Ingelheim starts patient recruitment in HCV drug trial
The Phase 3 trial will investigate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1 HCV. The company will recruit around 1,875 patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.